Patent ID: 11912763
Assignee: L & L BIOPHARMA CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 17:
18. The bispecific antibody as defined in claim 4, wherein the anti-PD-1 antibody is Nivolumab, Pembrolizumab or Ba08, the anti-PD-L1 antibody is Atezolumab, Avelumab or Durvalumab, the anti-CD47 antibody is hu5F9 or iMab, and the anti-CD3 antibody is an antibody constructed using the sequences of light and heavy chain variable regions that bind to CD3 in Blinatumomab or AMG420; or, the cytokine includes TGF3, IL10 and CSF-1, and the cytokine receptor includes TGFj3RII, IL10 receptor and CSF-1R.